The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunizationCOVID-19 질병 중증도에서 흉선의 역할: 항체 치료 및 예방접종에 대한 의미Review Published on 2021-03-042022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] adaptive immune responses addition aging antibodies antibody treatment assist Atherosclerosis Care childhood chronic disease convalescent serum COVID-19 COVID-19 disease COVID-19 vaccines disease explain Health High-dose hypertension immune senescence Immunity immunization immunosenescence implicated implication IMPROVE Inflammation Longevity management organ Patient prophylactically Regulation respond resulting severe COVID-19 disease thymic thymus treated type 2 diabetes [DOI] 10.1080/21645515.2020.1818519 PMC 바로가기 [Article Type] Review
Antibody Binding Epitope Mapping (AbMap) of Hundred Antibodies in a Single Run단일 실행에서 100개 항체의 항체 결합 에피토프 매핑(AbMap)Article Published on 2021-01-012022-09-12 Journal: Molecular & Cellular Proteomics : MCP [Category] 진단, [키워드] antibody binding binding epitope conformational convalescent serum COVID-19 COVID-19 patient defined diagnostics epitope epitope mapping functional information less linear linear epitope magnitude mapping Next-generation sequencing peptide phage display profile PROTECT random random peptide library. specific antibody Spike protein the antibodies [DOI] 10.1074/mcp.RA120.002314 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates2개의 RNA 기반 Covid-19 백신 후보의 안전성 및 면역원성Clinical Trial Published on 2020-12-172022-09-12 Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome added Adults age assigned BNT162b1 BNT162b2 candidate conducted convalescent serum coronavirus coronavirus disease defined disease dose dose-dependent dose-escalation doses Efficacy elicited ENCODE full-length geometric mean titer geometric mean titers Germany group healthy immunogenicity immunogenicity data incidence Infection Interim Local Multiple nucleoside-modified RNA observer-blinded of BNT162b2 Older participant Participants phase 1 trial Placebo placebo-controlled prefusion conformation Primary outcome randomization Randomly receive reported resulting Safety SARS-CoV-2 secondary outcome secreted severity spread to Support systemic reaction The United States the vaccine Trial Vaccine vaccine candidate vaccine dose [DOI] 10.1056/NEJMoa2027906 PMC 바로가기 [Article Type] Clinical Trial
Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidateOriginal Article Published on 2020-12-142022-10-31 Journal: Emerging Microbes & Infections [Category] COVID-19, SARS, [키워드] Analysis anti-SARS-CoV-2 vaccines Antibody Response antibody response against antigenic antigenicity Antisera caused cleavage cleaved clinical trial convalescent convalescent serum COVID-19 pandemic demonstrated elicit facilitate FIVE form forms full-length S glycoprotein glycosylated immunization immunized immunogenic inactivated Inactivated vaccine membrane Modification modifications natural infection Neutralizing antibodies pathogenesis of SARS-CoV-2 post-translational modification protease Protein purified Quality control S glycoprotein S protein S1 and S2 S1/S2 subunit S2 subunit SARS-CoV-2 SARS-CoV-2 virion sera shown stimulated structural protein structural proteins subunit subunits the vaccine vaccination Vaccine vaccine candidate Vero virion virions [DOI] 10.1080/22221751.2020.1855945 PMC 바로가기 [Article Type] Original Article
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and TreatmentsSARS-CoV-2: 감염 및 백신 및 치료제 개발로 유발되는 면역 반응Review Published on 2020-12-112022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome coronavirus addition administration affected antiparasitic antivirals approach approved caused characterized clinical clinical evidence clinical manifestation clinical manifestations Clinical stages clinical trial clinical trials contribute convalescent serum coronavirus coronavirus 2 coronavirus disease COVID-19 COVID-19 disease current therapy deaths described development disease distress drug dry cough effective Evidence exacerbated FDA Fever food Food and Drug Administration headache Health Organization Human Hydroxychloroquine immune Immune cell immune cells immune response immunological imperative Infection Infectious disease information mediators Migration monoclonal antibody monoclonal antibody therapy neutralize organ pandemic Phase III clinical trials potential therapy Prevent proinflammatory mediator proinflammatory mediators respiratory respiratory distress response SARS-CoV-2 SARS-CoV-2 patients severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Severe case severe cases Symptom tested therapy Treatment treatments Vaccine vaccine candidate Vaccines virus WHO World Health Organization [DOI] 10.3389/fimmu.2020.569760 PMC 바로가기 [Article Type] Review
Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility골든 시리아 햄스터 모델에서 코로나바이러스 질병 2019(COVID-19)의 임상 및 병리학적 징후 시뮬레이션: 질병 발병 및 전염성에 대한 의미Article Published on 2020-12-032022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료법, [키워드] ACE2 Activation adaptive airway alveolar damage angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal Antibody titer Antibody titers Apoptosis atrophy binding Blood change chemokine clinical Clinical sign Clinical signs Contact convalescent serum coronavirus COVID-19 Diffuse alveolar damage docking expression hamster hamsters histopathological Histopathology immunoprophylaxis initial intestinal involvement with Koch's postulates Laboratory lung Lung pathology lung viral load lymphoid mammal manifestation molecular docking Mortality Mutation Neutralizing antibody titer nonsynonymous option organ Pathogenesis pathological pathology performed physiological proliferative rapid breathing Receptor-binding domain resulting SARS-CoV-2 Serum neutralizing antibody significant decrease Simulation Spike protein spleen suggested the receptor-binding domain tissue tissue repair titer Transmission Treatment vaccination Viral Viral load viral nucleocapsid protein virus virus titer viruses weight loss [DOI] 10.1093/cid/ciaa325 PMC 바로가기 [Article Type] Article
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset증상 발병 후 4개월 이내에 종적 회복기 혈장 샘플에서 SARS-CoV-2 RBD 항체 약화Randomized Controlled Trial Published on 2020-11-262022-09-12 Journal: Blood [Category] SARS, 임상, 진단, [키워드] antibody Antibody titer convalescent plasma convalescent serum demonstrated Donor examined implication recovering from COVID-19 SARS-CoV-2 RBD serum symptom onset [DOI] 10.1182/blood.2020008367 PMC 바로가기 [Article Type] Randomized Controlled Trial
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals회복된 SARS 환자 및 면역된 동물의 혈청 항체에 의한 SARS-CoV-2의 교차 반응성 중화Article Published on 2020-11-062022-09-12 Journal: Science Advances [Category] SARS, 진단, [키워드] 2003 SARS acute respiratory syndrome analyzed Antisera caused collected convalescent serum coronavirus coronavirus disease Coronaviruses COVID-19 cross-neutralizing cross-reactive ectodomain Effect elicited full-length S immunized immunogen individual infections mice neutralization neutralize neutralized Novel coronavirus outbreak palm civet pandemic patient sera RBD Receptor binding domain recognize response S2 protein SARS patient SARS-CoV SARS-CoV infection SARS-CoV-2 SARS-CoV-2 S serum antibody the RBD the S1 subunit Vaccine [DOI] 10.1126/sciadv.abc9999 PMC 바로가기 [Article Type] Article
Identification and Tracking of Antiviral Drug CombinationsArticle Published on 2020-10-182022-10-28 Journal: Viruses [Category] COVID-19, MERS, SARS, [키워드] A549 cells acute respiratory syndrome addition Antiviral antiviral drug antiviral drug combinations antivirals broad-spectrum antivirals calu-3 cells cells Combination convalescent serum coronavirus cycloheximide demonstrated developmental drug Efficacy EIDD-2801 epithelial HCV hepatitis C virus HIV-1 HIV-1 infection homoharringtonine Human immunodeficiency virus human lung identification identify in vitro Infection infections monensin monotherapy neutralizing antibody Prevent purified reduced Remdesivir resource SARS-CoV-2 synergistic synergy therapy Toxicity treat treatment for HIV viral strain virus [DOI] 10.3390/v12101178 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsClinical Trial Published on 2020-09-292022-10-04 Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome Administered Adults adverse event age assigned binding CD4 chills conducted Control convalescent serum coronavirus coronavirus disease cytokine response death dose dose-dependent dose-escalation elicited ENCODE fatigue geometric mean titer GMT headache healthy immunization immunogenicity incidence include Infection Infectious disease injection Messenger RNA Mild moderate mRNA-1273 mRNA-1273 vaccine multiple methods myalgia Neutralizing activity Neutralizing-antibody neutralizing-antibody titer Older Older age older population Open-label Pain participant Phase 3 prefusion Prevent receive recipient reported response Result S-2P Safety SARS-CoV-2 SARS-CoV-2 spike protein serum severity stratified subgroup Support T cells Testing the median Trial type 1 helper Vaccine vaccine candidate vaccine trial [DOI] 10.1056/NEJMoa2028436 PMC 바로가기 [Article Type] Clinical Trial